Evolocumab cost effectiveness
Pro Research Analysisby 
Searched over 200M research papers
Evolocumab Cost-Effectiveness in Cardiovascular Disease
Cost-Effectiveness in the United States
Evolocumab, a PCSK9 inhibitor, has shown clinical benefits in reducing cardiovascular events, but its cost-effectiveness depends heavily on drug price and patient risk level. Earlier analyses at the original US list price ($14,523/year) found that evolocumab exceeded commonly accepted cost-effectiveness thresholds, with incremental cost-effectiveness ratios (ICERs) often above $150,000 per quality-adjusted life-year (QALY) gained. To meet a $150,000/QALY threshold, the annual price would need to drop to about $9,669 or be targeted to higher-risk populations . However, after a significant price reduction to $5,850/year, updated analyses found that evolocumab meets accepted cost-effectiveness thresholds for very high-risk patients, with ICERs ranging from $7,667 to $56,655 per QALY, especially when baseline cardiovascular event rates are high . Other studies also support cost-effectiveness in high-risk groups, such as those with familial hypercholesterolemia or statin intolerance, with ICERs below or near accepted US thresholds .
Cost-Effectiveness in China
In China, the cost-effectiveness of evolocumab varies by patient group and drug price. For adults with atherosclerotic cardiovascular disease (ASCVD) and LDL-C >70 mg/dL, evolocumab added to statins was found to be highly cost-effective, with an ICER of 14,969 CNY/QALY, well below the national willingness-to-pay threshold . In patients with recent acute coronary syndrome (ACS) or myocardial infarction (MI), evolocumab was also cost-effective compared to ezetimibe or placebo, with ICERs of 85,964–87,050 CNY/QALY and a 100% probability of being cost-effective at the accepted threshold Xi2021Xi2022. However, at higher drug prices, such as the 2019 list price, evolocumab was not cost-effective for general MI patients unless the price was reduced by about 70% or the therapy was targeted to those with familial hypercholesterolemia .
Cost-Effectiveness in Canada
Canadian analyses show mixed results. One study found that at current prices, evolocumab is unlikely to be cost-effective for secondary prevention, with a cost per year of life saved (YOLS) of $299,482 CAD. The annual drug cost would need to fall below $2,300 CAD to meet a $100,000/YOLS threshold . However, another analysis using updated guidelines and patient selection criteria found that evolocumab could be considered cost-effective in high-risk ASCVD patients, with an ICER of $66,453 CAD/QALY, below the $100,000 CAD threshold .
Systematic Review and Key Influencing Factors
A systematic review of 16 studies from various countries found that evolocumab can be cost-effective, especially in high-risk populations, but results vary widely depending on LDL-C levels, drug price, and disease type. Reported ICERs ranged from $3,343 to over $2.6 million per QALY, highlighting the importance of patient selection and local pricing. Sensitivity analyses consistently showed that lower LDL-C, lower drug costs, and higher baseline cardiovascular risk improve cost-effectiveness .
Conclusion
Evolocumab’s cost-effectiveness is highly dependent on drug price, patient risk profile, and local healthcare system thresholds. It is generally cost-effective for very high-risk patients or when drug prices are substantially reduced. In lower-risk populations or at higher prices, it often exceeds accepted cost-effectiveness thresholds. Policymakers and clinicians should consider these factors when deciding on the use of evolocumab for cardiovascular risk reduction Fonarow2017Xie2022Fonarow2019+7 MORE.
Sources and full results
Most relevant research papers on this topic
Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective
Evolocumab therapy is not cost-effective for patients with myocardial infarction in China, but is more favorable for those with familial hypercholesterolemia.
Cost-effectiveness Analysis of Evolocumab in Patients With Recent Acute Coronary Syndrome in China
Evolocumab is considered cost-effective compared to ezetimibe in patients with a recent acute coronary syndrome event in China, with a QALY gain of 1.41 and incremental costs of 120,966 yuan.
DOI